Taxotere Prostate Cancer New Indication Registration Trial in China

Inclusion criteria

• Histologically or cytologically proven prostate adenocarcinoma
• Androgen independent prostate Cancer S/P orchiectomy and/or LHRH agonist Testosterone < 50 ng/dl (ie 1.735 nmol/l)
• Documented progressive disease
• Patients should have achieved stable analgesia for 7 days
• Karnofsky Performance Status ≥ 70
• No prior treatment with cytotoxic agent (except estramustine)
• Normal cardiac function must be confirmed by Left ventricular ejection fraction
• Adequate organ function:

• Hematology:

• Neutrophils > 1.5 x 10^9/L
• Hemoglobin > 10 g/dl. Erythropoietin use is allowed, but red blood cell transfusion to upgrade the hemoglobin level is not allowed
• Platelets > 100 x 10^9/L
• Hepatic function:

• Total bilirubin < the upper-normal limit of the institution.
• Alanine aminotransferase and Aspartate transaminase < 1.5 times the upper-normal limit of the institution.
• Renal function:

• Creatinine < 1.5 times the upper normal limit (ie National Cancer Institution grade < 1)
• No brain or leptomeningeal metastases

Exclusion criteria

• Prior radiotherapy to >25% of bone marrow (whole pelvic irradiation is not allowed)
• prior cytotoxic chemotherapy, except monotherapy with estramustine
• prior isotope therapy
• history of another cancer within the preceding five year
• symptomatic peripheral neuropathy grade ≥ 2
• other serious illness or medical condition:

• Congestive heart failure even if controlled. Previous history of myocardial infarction or angina pectoris within 1 year from study entry, uncontrolled hypertension or uncontrolled arrhythmias.
• Active uncontrolled infection
• Peptic ulcer, unstable diabetes mellitus or other contraindications for the use of corticosteroids.
• Auto-immune disease (lupus, sclerodermia, rheumatoid polyarthritis)
• treatment with any other anti-cancer therapy
• treatment with bisphosphonates

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.